Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · CFR · Title 21 — Food and Drugs · Part 25 — Environmental Impact Considerations · § 25.31

§ 25.31. Human drugs and biologics.

299 words·~1 min read·/us/cfr/t21/s§ 25.31·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

The classes of actions listed in this section are categorically excluded and, therefore, ordinarily do not require the preparation of an EA or an EIS:
(a)Action on an NDA, abbreviated application, application for marketing approval of a biologic product, or a supplement to such applications, or action on an OTC monograph, if the action does not increase the use of the active moiety.
(b)Action on an NDA, abbreviated application, or a supplement to such applications, or action on an OTC monograph, if the action increases the use of the active moiety, but the estimated concentration of the substance at the point of entry into the aquatic environment will be below 1 part per billion.
(c)Action on an NDA, abbreviated application, application for marketing approval of a biologic product, or a supplement to such applications, or action on an OTC monograph, for substances that occur naturally in the environment when the action does not alter significantly the concentration or distribution of the substance, its metabolites, or degradation products in the environment.
(d)Withdrawal of approval of an NDA or an abbreviated application.
(e)Action on an IND.
(f)Testing and release by the Food and Drug Administration of lots or batches of a licensed biologic product.
(g)Establishment of bioequivalence requirements for a human drug or a comparability determination for a biologic product subject to licensing.
(h)Issuance, revocation, or amendment of a standard for a biologic product.
(i)Revocation of a license for a biologic product.
(j)Action on an application for marketing approval for marketing of a biologic product for transfusable human blood or blood components and plasma. [62 FR 40592, July 29, 1997, as amended at 63 FR 26697, May 13, 1998; 64 FR 399, Jan. 5, 1999; 70 FR 14980, Mar. 24, 2005]
Connections113 cite this
Cited by 113 sections · top 60
register
Citation graph
cites case law
§ 25.31
Human drugs and biologics.
Fed. Reg.×112
C.F.R.×1
Cites 0Cited by 113 across 2 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.